alpha-methyl-4-deoxy-4-[(18)f]fluoro-d-glucopyranoside
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2023 (NCT05558904)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05558904 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2023 | American Cancer Society, Inc., LUNGevity Foundation, University of California, Los Angeles |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| American Cancer Society, Inc. | Academic/Hospital | 1 | 0 | 1 | 2023 |
| LUNGevity Foundation | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1